Cath Lab Digest

Uluru Inc (Addison, Tex) presented results from the first completed randomized clinical trial for Altrazeal™ Transforming Powder Dressing at the Symposium on Advanced Wound Care (SAWC) Fall Symposium, which took place in Washington D.C., September 16–18, 2009. The dressing utilizes proprietary nanoflex™ technology to promote the healing of exuding wounds. The recently completed clinical study compared healing, pain, and comfort of skin graft donor sites treated with either the dressing or with a leading commercial sodium carboxymethylcellulose-silver (“CMC-Ag”) dressing. Major results from the study indicated a significant difference in patient’s pain scores, all favoring the dressing with lower pain scores at each time point (P <0.001). When asked about the comfort of the wound dressing at the edges, tstudy subjects rated the dressing more comfortable (P <0.001) and less painful when the dressing came in contact with clothes or bedding (P <0.001). The study endpoints validated the hypothesis for time to healing for both dressings in this particular type of acute surgical wound.

The study was a single center, prospective randomized trial in which each patient served as his/her own control. Each patient had at least two split-thickness donor sites: one was dressed with the study dressing and the other with the CMC-Ag dressing. In addition to the randomized clinical trial, more clinical evidence on the treatment of various wound types using the transforming powder dressing were presented on multiple posters during the symposium.

For more information, visit www.uluruinc.com.